I saw that. Although it wasn't highly favourable given a neutral rating. My gut feeling is that this is a medium to long term play about 3-5 years. The market for heart pumps is hard to work out but the potential is still huge. Given Cochlear is a AUS$4billion company today, there's no reason why Heartware cannot replicate that in US$ terms in the next 3-5 years so long as the patient data remains on track.
Note that Thoratec (THOR) is a US$2.56 billion company today while HWTR (Heartware) is US$900 billion and they still do not have a next generation pump in the making.
Very pie in the sky stuff but the medical business is like that. Lets just wait and see.
Add to My Watchlist
What is My Watchlist?